UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)
July 31, 2023

SANUWAVE Health, Inc.
(Exact name of registrant as specified in its charter)

Nevada
000-52985
20-1176000
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)

11495 Valley View Road, Eden Prairie, Minnesota
 
55344
(Address of principal executive offices)
 
(Zip Code)

Registrant’s telephone number, including area code
(770) 419-7525

N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each class
 
Trading Symbol(s)
 
Name of each exchange on which
registered
N/A
 
N/A
 
N/A
Indicate by check mark whether the registration is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Effective July 31, 2023, the Board of Directors of SANUWAVE Health, Inc. (the “Company”) appointed Andrew Walko as the Company’s President. Mr. Walko brings deep experience in contract manufacturing, supply chain management, medical device production, and logistics from his previous roles as President at Biomerics, LLC (medical device contract manufacturing) from August 2021 to April 2023; at Minnetronix, Inc. (medical device design and manufacturing), including as Director of Manufacturing (Operations) from March 2020 to July 2021 and Senior Manager, Manufacturing (Operations) from June 2018 to February 2020; and at Integer Holdings Corporation.  Prior to this, he served as Operations and Logistics Manager for U.S. Army operations/special operations both at home and overseas.  He earned his MBA from the University of Minnesota.

In connection with his appointment as President, the Company and Mr. Walko entered into an offer letter, dated July 20, 2023 (the “Offer Letter”). Pursuant to the Offer Letter, Mr. Walko will (i) receive an annual base salary of $230,000, (ii) be eligible to earn an annual bonus of 25% of his base salary, based on the achievement of performance goals established by the Company, and (iii) receive an option grant to purchase 22.5 million shares of the Company’s common stock during the quarter his employment commences, which option grant will vest in three equal tranches at each of 12, 24 and 36 months of employment.  The option grant will vest in full upon a change of control or other similar events. The foregoing summary of the Offer Letter is qualified in its entirety by reference to the full text of the Offer Letter, a copy of which is filed as Exhibit 10.1 hereto and incorporated herein by reference.
 
On July 31, 2023, the Company and Mr. Walko entered into a Non-Compete and Confidentiality Agreement (the "Non-Compete and NDA"), pursuant to  which Mr. Walko agreed to keep all confidential, proprietary or trade secret knowledge, data or information of the Company and its affiliates confidential during the term of his employment and for a period of two years thereafter.  Mr. Walko also agreed not to solicit any employees, consultants or customers of the Company or compete with the Company during the term of his employment and for a period of one year thereafter. The foregoing summary of the Non-Compete and NDA is qualified in its entirety by reference to the full text of the Non-Compete and NDA, a copy of which is filed as Exhibit 10.2 hereto and incorporated herein by reference.

Mr. Walko has no family relationship with any director or executive officer of the Company, and no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.
 

Item 7.01
Regulation FD Disclosure.

On July 31, 2023, the Company issued a press release announcing Mr. Walko’s appointment as President. A copy of the press release is attached hereto as Exhibit 99.1.

The information in this Item 7.01, and Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, regardless of any general incorporation language in such filing.

Item 9.01
Financial Statements and Exhibits.

(d)
Exhibits.

Exhibit
No.
 
Description
     
 
Offer Letter, dated July 20, 2023, by and between the Company and Andrew Walko
10.2

Non-Compete and Confidentiality Agreement, dated July 31, 2023, by and    between the Company and Andrew Walko
 
Press Release dated July 31, 2023
104
 
Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
SANUWAVE HEALTH, INC.
     
Dated: July 31, 2023
By:
/s/ Toni Rinow
 
Name:
Toni Rinow
 
Title:
Chief Financial Officer




Exhibit 10.1


July, 18 2023

Dear Andrew,

SANUWAVE, Inc. ("Company") is pleased to offer you the position of President Your start date will be (TBD). We are confident that your acceptance marks the beginning of a challenging and mutually beneficial relationship.

This written offer will expire on M onday1   July 241   2023, at midnight eastern standard time, if not accepted by you before that time. Acceptance of this offer includes 1) signing and returning this letter as well as 2) completing the enclosed Non-Compete and Confidentiality Agreement, Statement Regarding Insider Trading and Code of Business Conduct/Ethics.

COMPENSATION Semi-monthly, exempt compensation will be $230,000 annually, less payroll deductions and required withholdings, paid on the 15th and last day of each month. Should termination of employment occur through no fault of employee severance allowance would be equal to four (4) months base salary.

BONUS COMPENSATION You will be eligible to earn an annual bonus of 25%, based on the achievement of performance goals established by the Company .

EQUITY COMPENSATION Employee will receive an employee equity options grant of options to purchase 22.5 million shares (1.5% of current shares outstanding) struck at market price in the quarter employment commences and that will vest on a schedule 10 million each at 12, 24, and 36 months of employment subject to standard acceleration provisions to provide for full vesting around change of control or other similar events.

BENEFITS As a full-time employee, you are eligible to participate in our benefits package including medical, dental, vision, life insurance, short-term and long-term disability benefits, as well as the Company 401(k) plan. You are eligible starting the first month following your start dat e.

Once you begin employment with SANUWAVE, you will be given access  to  Paychex  Flex  self-service.  Please visit this site immediately as there are activities due within 72 business hours of your start date. Information regarding enrollment in benefit plans will be sent in a separate email and must  be completed  within  30 days  of your start date.

CPE REIMBURSEMENT. The Company commits to reimburse you for CPE, (Continuing Professional Education), course expenses, up to $1,500 .00 per fiscal year, for courses taken while you are an active employee in good standing with the Company.

11495 Valley View Road •Eden Prairie, MN 55344 USA• +l 770.419.7525 (p) • +l 770.419.8634 (f) • www.sanuwave.com




VACATION: Paid vacation shall be 3 weeks per annum.

COMPLIANCE WITH RULES You will be expected to abide by all SANUWAVE rules, regulations, and Company Policies. Throughout your employment, you are responsible for advising the CEO or Human Resources of any factors that may affect your ability to work for the Company without interrupt ion.

RIGHT OF INSPECTION. You acknowledge and agree that the Company has unlimited access to your equipment and work product when it's deemed to be necessary and may inspect, with or without notice.

AT-WILL EM PLOYM EN T. As an at-will employee, you may terminate your employment at any time, with or without cause. Likewise, as an at-will employer, the Company may terminate your employment at any time, with or without cause. The Company also retains the right to make all other decisions concerning your employment (e.g., promotions, demotions, job responsibilities, or any other managerial decisions) with or without cause, in the exercise of its discret ion . This at-will employment relationship cannot be changed except in a writing signed by you and the CEO .

NON-COMPETE, CONFIDENTIALITY AGREEMENT, INSIDER TRADING AND CODE OF BUSINESS CONDUCT /ETHICS. You are required to sign the enclosed Non-Compete and Confidentiality Agreement, Statement Regarding Insider Trading and Code of Business Conduct/Ethics and return it with other items included in the complete offer package you will receive.

ENTIRE AGREEMENT; NO MODIFICATIONS. This . l et t er is the final and exclusive embodiment of the entire agreement between you and the Company with respect to the terms and conditions  of  your  employment,  and they supersede any promises or representations made to you by anyone, whether oral or written.

Please sign, date, and EMAIL this letter as acceptance of our offer of employment and in agreement with the terms described in this letter to hr@sanuwave.com. Shortly after accepting this offer, you will be sent a release for Criminal and Employment Background Check. This offer and start date are contingent upon the successful results of the background check . Please complete the release within 48 hours.

Very truly yours,

Morgan Frank, CEO
Sanuwave, Inc.

11495 Valley View Road •Eden Prairie, MN 55344 USA• +l 770.419.7525 (p) • +l 770.419.8634 (f) • www.sanuwave.com



ACCEPTED AND AGREED TO: Andrew Walko

   
/s/ Andrew Walko
/s/ Andrew Walko
Name Printed
Name Signed

11495 Valley View Road •Eden Prairie, MN 55344 USA• +l 770.419.7525 (p) • +l 770.419.8634 (f) • www.sanuwave.com




Exhibit 10.2


Non- Compete and Confidentiality Agreement
 
In consideration of my employment or continued employment by SANUWAVE Health, Inc. (the "Company"), the Company's disclosure of certain Proprietary Information (as defined below) to me, any compensation now and/or hereafter paid to me, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the undersigned hereby agrees with the Company as follows:
 
1.   Definitions.
 
a.      The term "Proprietary Information" shall mean any and all confidential, proprietary or trade secret knowledge, data or information of the Company and its affiliated entities, including but not limited to the Company's strategic plans, inventions, new products, product plans, product prices, consumer marketing research, strategies, and information, business results and financial information, ideas, processes, formulas, source and object codes, data, computer programs, algorithms, database developments, designs and techniques, costs, research and development, know-how, customer lists, and information; potential customer information, potential acquisitions and divestitures, specialized training, the identity, skills and compensation of employees, contractors, vendors, suppliers, and consultants, and any other confidential, proprietary or trade secret knowledge, data or information, in whatever form or medium, produced by or for the Company.
 
b.         The term "Third Party Information" means confidential or trade secret information that the Company may from time to time receive from third parties or information which is subject to a duty on the Company's part to maintain the confidentiality of such Third Party Information and to use it only for certain limited purposes.
 
2.         Recognition of Company's Rights; Nondisclosure: I acknowledge that contemporaneously with my execution of this Agreement, the Company is providing me with Proprietary Information and/or specialized training. In consideration  of  the  Company's provision of Proprietary Information and initial specialized training, I agree that during my employment and for a period of (2) years thereafter, pursuant to this Agreement, I will hold in strictest confidence and will not disclose, discuss, transmit, use, lecture upon, or publish any Proprietary Information, unless such disclosure  (i) is required in connection  with my work for the Company, or (ii) is expressly authorized in writing by an officer of the Company. I  also  agree that in connection with this Agreement, I will also be bound by the post-employment provisions of paragraph 9. I further acknowledge and agree that the Company's conduct in providing me with Proprietary Information in exchange for my Agreement gives rise to the Company's interest in restraining me from competing  against the Company after the conclusion of my employment as set forth in paragraph 9 (the "Non-Compete Clause"), and that my agreement to the Non-Compete Clause is designed to enforce my Agreement. To the extent that any such Proprietary Information should constitute a trade secret under applicable law, my obligations of confidentiality and non-disclosure as set forth herein shall continue to survive after said (2) year period to the greatest extent permitted by applicable law.
 

3.        Third Party Information: I understand that the Company has received and in the future will receive from third parties Third Party Information subject to a duty on the Company's part to maintain the confidentiality of such information and to use it only for certain limited purposes. During the term of my employment for a period of (2) years and thereafter, I will hold such Third Party Information in the strictest confidence and will not disclose (to anyone other than Company personnel who need to know such information in connection with their work for the Company) or use, except in connection with my work for the Company, Third Party Information unless expressly authorized by an officer of the Company in writing. To the extent that any such Third Party Information shall be a trade secret under applicable law, then my obligations of confidentiality and non-disclosure shall survive after said two (2) year period to  the greatest extent permitted by applicable law.
 
4.          Property Rights: All right, title, and interest in and to all results and products of any services I perform for or on behalf of the Company shall at all times be and remain the sole and exclusive property of the Company, whether such results and products are interim or final, tangible or intangible. Such results and products include, without limitation, every invention, mask work, work of authorship, formula, trade secret, computer program (including without limitation, object code, source code, listings, routines, flow charts, algorithms and related documentation), manual, specification, technique, product, concept, know-how or similar property, whether or not patentable or copyrightable and whether or not embodied in  any tangible form, that are made, developed, perfected, designed conceived or first reduced to practice by me, either solely or jointly with others, in the course and scope of services I perform for or on behalf of the Company.

I further agree that any patent, copyright, trade secret, trademark, mask work or other intellectual property rights that may arise from services I perform for or on behalf of the Company shall be in the name of, and are hereby exclusively assigned to, the Company. I shall without further consideration execute and deliver such instruments, and take such other actions, as the Company may reasonably require to establish, evidence, maintain, defend or enforce the exclusive ownership by the Company of such intellectual property rights and of any tangible works or property produced by me in the course of performing services for or on behalf of the Company.
 
5.        No Improper Use of Materials: During my employment by the Company I will  not improperly use or disclose any confidential information or trade secrets, if any, of any former employer or any other person to whom I have an obligation of confidentiality. I will not bring onto Company premises any materials belonging to any former employer or any other person to whom I have an obligation of confidentiality without the consent of the former employer or person and the approval of my direct supervisor.


6.          No Conflicting Obligations: I represent that my performance of all the terms of this Agreement and as an employee of the Company does not and will not breach any agreement to keep in confidence information acquired by me in confidence or in trust prior to my employment by the Company. I have not entered into, and I agree I will not enter into, any agreement either written or oral in conflict herewith.
 
7.          Return of Company Documents and Other Company Property: When I leave the employ of the Company, I will immediately deliver to the Company any and all drawings, notes, memoranda, specifications, devices, formulas, and documents together with all copies thereof; and any other material containing or disclosing any Third Party Information or Proprietary Information of the Company. I will also immediately return all Company property, including but not limited to laptops, pagers, cell phones, corporate credit cards, keys, and/or access cards.
 
8.          Non-Solicitation: I agree that during the period of my employment by the Company and for one (1) year after the date of termination  of my employment  by the Company, I will not (i) solicit, assist or in any way encourage any current employee or consultant of the Company to terminate his or her employment relationship or consulting relationship with or for the Company, nor will I solicit the services of any former employee of the Company whose service has been terminated for less than three (3) months; nor will I (ii) solicit to the detriment  of the Company and/or for the benefit of any competitor of the Company,  take away or attempt to take away, in whole or in part, any Customer of the Company or otherwise interfere with the Company's relationship with any Customer. For purposes of this paragraph, "Customer" shall mean each of Company's customers and actively sought prospective customers with whom I had material contact with during my employment, meaning customers (i) with whom I dealt within the past two years of my employment (ii) whose dealings with Company were coordinated or supervised by me: or (iii) about whom I obtained confidential information in the ordinary course of business through my association with Company. The restrictions contained herein area agreed to be reasonable, and it is further agreed that if Company ceases to provide any such product or service, the foregoing restriction with respect to such product or service shall terminate as  of such date.
 
9.         Non-Competition: During my employment and for a period of one (1) year after the date that my employment is terminated, for any reason, I will not, directly or indirectly, in the state in which I am employed, (i) compete with the Company in Business or (ii) participate in the ownership, management, operation, financing, or control of, or be employed in the same or substantially similarly capacity as I was when working for the company or consult for or otherwise render services to, any person, corporation, firm, or other entity that competes with the Company in Business. Notwithstanding the foregoing, I am permitted to own up to 1% of any class of securities of any corporation in competition with the Company that is traded on  a national securities exchange or through Nasdaq. For the purposes of this  Paragraph  9, "Business" shall mean those portions of the Company's business in which I actively participated or regarding which I received Proprietary Information in the business of developing and utilizing Extracorporeal Shock Wave Technology (ESW) and SANUWAVE's Pulsed Acoustic Cellular Expression PACE® technology for advanced wound care, orthopedic, cardiovascular, and spine/neurological for human medical purposes (the "Business").
 
10.       Equitable Remedies: Because my services are personal and unique and because I will have access to and become acquainted with Proprietary Information, the Company shall have the right to enforce this Agreement and any of its provisions by injunction, specific performance, or other equitable relief, without bond and without prejudice to any other rights and remedies that the Company may have for a breach of this Agreement.
 

11.       Successors and Assigns: This Agreement will be for the benefit of the Company, its successors and assigns. I expressly agree that the Company has the right to assign this Agreement.
 
12.       Governing Law; Exclusive Forum: This Agreement will be governed by and construed according to the laws of the State of Georgia. I hereby irrevocably agree that the exclusive forum for any suit, action, or other proceeding arising out of or in any way related to this Agreement shall be in the state or federal courts in Georgia, and I agree to the exclusive personal jurisdiction and venue of any court in Fulton County, Georgia and waive any defense thereto.

13.        Entire Agreement: This Agreement is the final, complete and exclusive agreement of the parties with respect to the subject matter hereof and supersedes and merges all prior discussions between us. No modification of or amendment to this Agreement, nor any waiver of any rights under this agreement, will be effective unless in writing signed by both parties. Any subsequent change or changed in my duties or compensation will not affect the validity or scope of this Agreement. As used in this Agreement, the period of my employment includes any time during which I subsequently may be retained by the Company as a consultant.
 
14.       Severability: If one or more of the provisions in this Agreement are deemed unenforceable by law, then the remaining provisions will continue in full force and effect. Moreover, it is intended by the parties that this Agreement is to be enforced to the fullest extent permitted by law. Accordingly, if a court of competent jurisdiction determines that the scope and/or operation of any provision of this Agreement is too broad to be enforced as written, the Company and I intend that the court should reform such provision to such narrower scope and/or operation as it determines to be enforceable

15.       Survival: The provisions of this Agreement shall survive the termination of my employment and shall inure to the benefit of any successor in interest of the Company or other assignee.

I AGREE AND UNDERSTAND THAT NOTHING IN THIS AGREEMENT SHALL CONFER ANY RIGHT WITH RESPECT TO CONTINUATION OF EMPLOYMENT  BY THE COMPANY, NOR SHALL IT INTERFERE IN ANY WAY WITH MY RIGHT OR THE COMPANY'S RIGHT TO TERMINATE MY EMPLOYMENT AT ANY TIME, WITH OR WITHOUT CAUSE.


THIS AGREEMENT SHALL BE EFFECTIVE AS OF THE FIRST DAY OF MY EMPLOYMENT WITH THE COMPANY.
 
I UNDERSTAND THAT THIS AGREEMENT RESTRICTS THE DISCLOSURE AND/OR USE OF THE COMPANY'S PROPRIETARY AND CONFIDENTIAL INFORMATION DURING OR SUBSEQUENT TO MY EMPLOYMENT WITH THE COMPANY, AND THAT IT RESTRICTS MY ABILITY TO SOLICIT CUSTOMERS AND EMPLOYEES OF THE COMPANY AND RESTRICTS MY ABILITY TO COMPETE WITH THE COMPANY FOLLOWING THE TERMINATION OF MY EMPLOYMENT.
 
I HAVE READ THIS AGREEMENT CAREFULLY AND UNDERSTAND ITS TERMS.

July 31, 2023

Andrew Walko


Date

Name

ACCEPTED AND AGREED TO:

SANUWAVE Health, Inc.



By:
CLARISSA MICHENER

ASSOCIATE DIRECTOR OF HR


Date:
July 31, 2023




Exhibit 99.1

SANUWAVE Health Appoints Industry Veteran Andrew Walko as President
 
SANUWAVE Health, Inc.
July 31, 2023
 


Walko brings 17 years of Manufacturing, Production, Operations, and Logistics Experience, most recently as President of Biomerics, where he led a 170-person contract manufacturing organization

EDEN PRAIRIE, MN, July 31, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – SANUWAVE Health, Inc. (the "Company" or "SANUWAVE”) (OTCQB: SNWV), a leading provider of next-generation FDA-approved wound care products, is pleased to announce the hiring of Andrew Walko as its new President.  Walko brings deep experience in contract manufacturing, supply chain management, medical device production, and logistics from his previous roles at Biomerics, Minnetronix Medical, and Integer Holdings.  Prior to this, he served as operations and logistics manager for U.S. Army operations/special ops both at home and overseas.  He earned his MBA from the University of Minnesota.
 
“We are pleased to welcome Andrew to SANUWAVE at this pivotal time in our growth plans,” said CEO Morgan Frank.  “His experience, energy, and attitude are going to be a strong addition to our team and provide us with the skills and talent we need to take the next steps forward in expanding our manufacturing capabilities and becoming a leader in the wound care space.”
 
“I can’t be more thrilled to join SANUWAVE at this exciting time in its journey. We have a great opportunity in front of us to deliver critical therapy to patients and provide them with the best products and care available.” said Walko.  “I look forward to contributing to the future growth of this important technology.”
 
Andrew begins work at SANUWAVE on July 31, 2023.
 

About SANUWAVE
 
SANUWAVE Health is focused on the research, development, and commercialization of its patented, non-invasive and biological response-activating medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures.
 
SANUWAVE’s end-to-end wound care portfolio of regenerative medicine products and product candidates help restore the body’s normal healing processes. SANUWAVE applies and researches its patented energy transfer technologies in wound healing, orthopedic/spine, aesthetic/cosmetic, and cardiac/endovascular conditions.
 
Forward-Looking Statements
 
This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future business development activities and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with the regulatory approval and marketing of the Company’s product candidates and products, unproven pre-clinical and clinical development activities, regulatory oversight, the Company’s ability to manage its capital resource issues, competition, and the other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.
 
Contact: investors@sanuwave.com
 


v3.23.2
Document and Entity Information
Jul. 31, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jul. 31, 2023
Entity File Number 000-52985
Entity Registrant Name SANUWAVE Health, Inc.
Entity Central Index Key 0001417663
Entity Incorporation, State or Country Code NV
Entity Tax Identification Number 20-1176000
Entity Address, Address Line One 11495 Valley View Road
Entity Address, City or Town Eden Prairie
Entity Address, State or Province MN
Entity Address, Postal Zip Code 55344
City Area Code 770
Local Phone Number 419-7525
Entity Emerging Growth Company false
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false

SANUWAVE Health (QB) (USOTC:SNWV)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024 SANUWAVE Health (QB) 차트를 더 보려면 여기를 클릭.
SANUWAVE Health (QB) (USOTC:SNWV)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024 SANUWAVE Health (QB) 차트를 더 보려면 여기를 클릭.